Micro Glucagon During Exercise in Type 1 Diabetes

Summary

This proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during moderate-intensity exercise in people with T1D.

Timeline

Start

2023-04

Primary completion

2024-04

Completion

2024-06

Drugs

Indications